SciClone Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Highlights
SciClone Pharmaceuticals Inc (SciClone), a subsidiary of Silver Biotech Investment Ltd, develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin) is an immunostimulatory agent indicated for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), sepsis, certain cancers, and as an immune system enhancer. SciClone also markets other pharmaceutical products in China including DC Bead, a product for the embolization of malignant hypervascularized tumors. It also has several drug candidates in various clinical development states intended for the treatment of cancer and cardiovascular diseases. The company has presence in Beijing and Shanghai in China; Hong Kong and Vietnam. SciClone is headquartered in Foster City, California, the US.
SciClone Pharmaceuticals Inc Key Recent Developments
Aug 09, 2017: SciClone Reports Second Quarter 2017 Financial Results
May 10, 2017: SciClone Reports First Quarter 2017 Financial Results
Mar 06, 2017: SciClone Reports 2016 Financial Results And 2017 Outlook
Reasons to buy
Note: Some sections may be missing if data is unavailable for the company.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Summarization of the company’s business strategy.
- SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
Highlights
SciClone Pharmaceuticals Inc (SciClone), a subsidiary of Silver Biotech Investment Ltd, develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin) is an immunostimulatory agent indicated for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), sepsis, certain cancers, and as an immune system enhancer. SciClone also markets other pharmaceutical products in China including DC Bead, a product for the embolization of malignant hypervascularized tumors. It also has several drug candidates in various clinical development states intended for the treatment of cancer and cardiovascular diseases. The company has presence in Beijing and Shanghai in China; Hong Kong and Vietnam. SciClone is headquartered in Foster City, California, the US.
SciClone Pharmaceuticals Inc Key Recent Developments
Aug 09, 2017: SciClone Reports Second Quarter 2017 Financial Results
May 10, 2017: SciClone Reports First Quarter 2017 Financial Results
Mar 06, 2017: SciClone Reports 2016 Financial Results And 2017 Outlook
Reasons to buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with this detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
Section 1 - About the Company- SciClone Pharmaceuticals Inc - Key Facts
- SciClone Pharmaceuticals Inc - Key Employees
- SciClone Pharmaceuticals Inc - Key Employee Biographies
- SciClone Pharmaceuticals Inc - Major Products and Services
- SciClone Pharmaceuticals Inc - History
- SciClone Pharmaceuticals Inc - Company Statement
- SciClone Pharmaceuticals Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
Section 2 - Company Analysis
- Company Overview
- SciClone Pharmaceuticals Inc - Business Description
- SciClone Pharmaceuticals Inc - SWOT Analysis
- SWOT Analysis - Overview
- SciClone Pharmaceuticals Inc - Strengths
- SciClone Pharmaceuticals Inc - Weaknesses
- SciClone Pharmaceuticals Inc - Opportunities
- SciClone Pharmaceuticals Inc - Threats
- SciClone Pharmaceuticals Inc - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
- SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
- SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
- SciClone Pharmaceuticals Inc, Recent Deals Summary
Section 4 - Company’s Recent Developments
- Aug 09, 2017: SciClone Reports Second Quarter 2017 Financial Results
- May 10, 2017: SciClone Reports First Quarter 2017 Financial Results
- Mar 06, 2017: SciClone Reports 2016 Financial Results And 2017 Outlook
Section 5 - Appendix
- Methodology
- About
- Contact
- Disclaimer
List of Tables
- SciClone Pharmaceuticals Inc, Key Facts
- SciClone Pharmaceuticals Inc, Key Employees
- SciClone Pharmaceuticals Inc, Key Employee Biographies
- SciClone Pharmaceuticals Inc, Major Products and Services
- SciClone Pharmaceuticals Inc, History
- SciClone Pharmaceuticals Inc, Subsidiaries
- SciClone Pharmaceuticals Inc, Key Competitors
- SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
- SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
- SciClone Pharmaceuticals Inc, Recent Deals Summary
List of Figures
- SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
- SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sarepta Therapeutics Inc
- Inovio Pharmaceuticals Inc
- Hemispherx Biopharma Inc
- Celldex Therapeutics Inc
- Alnylam Pharmaceuticals Inc
